Ismail Lourido Ali (MAPS): The Work No Executive Order Can Do

Ismail Lourido Ali (MAPS): The Work No Executive Order Can Do

"We can pass 10 executive orders. We can put $500 million for drug development. And if we don't have people who are willing to hold that space... we're not going to get anywhere." - Ismail Lourido Ali, MAP Co-CEO
On April 18th, just days before 420, Bicycle Day and MAPS’ own 40th anniversary, Donald Trump signed an executive order on psychedelics. But what does it mean? Especially for psychedelic practitioners themselves.


Today on the Psychedelic Therapy Podcast I sit down with MAPS Co-Executive Director Ismail Lourido Ali to learn what it actually means for the people doing the work. Together we unpack the executive order from the ground up: what it legally can and can't do, why ibogaine has suddenly kicked down the door while MDMA and psilocybin wait in line, and the strange political alchemy that made this happen. We cover the key distinctions between decriminalization, medicalization, and legalization; MAPS' evolving role as a multicultural bridge-builder at this pivot point; the sovereignty of Gabon and the very real risks of biopiracy in ibogaine's commercialization; and the danger of silver-bullet thinking. The conversation ends with the practitioners themselves, and the irreplaceable human work of preparation, presence, and integration that no executive order can replicate.


Ismail Lourido Ali, JD is the Co-Executive Director of MAPS (Multidisciplinary Association for Psychedelic Studies) alongside co-director Betty Aldworth. A philosopher by training and a lawyer by vocation, he previously served as MAPS Director of Policy, worked in criminal justice reform at the ACLU of Northern California, and co-founded the Psychedelic Bar Association. He has been active in psychedelic drug policy reform for over a decade.


Timestamps:

  • (01:00) Ismail's first six months as MAPS Co-CEO
  • (07:00) Decrim, medicalization, legalization
  • (12:00) What Trump's executive order actually does (and doesn't do)
  • (19:00) Why ibogaine? Origins, the opioid crisis, and the perfect storm
  • (30:00) The political alchemy behind the signing
  • (34:00) Where MAPS fits in this pivotal moment
  • (46:00) The Nagoya Protocol, Gabon's sovereignty, and the risk of biopiracy
  • (56:00) Silver bullets vs. real healing


Links:

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(64)

Robin Arnott & Sandeep Prakash: Training for Psychedelic Surrender

Robin Arnott & Sandeep Prakash: Training for Psychedelic Surrender

Can we practice the art of surrender before the first dose?Today on the show Robin Arnott and Dr. Sandeep Prakash explain how SoundSelf evolved from a VR curiosity into a clinically oriented tool that...

25 Huhti 202555min

Joshua White: Who You Gonna Call? Fireside

Joshua White: Who You Gonna Call? Fireside

Imagine you’re in the middle of a psychedelic journey—things are getting intense, and you just need someone to talk to. That’s whereFireside Project comes in. As the world’s first psychedelic peer sup...

13 Helmi 20251h 14min

Tom Feegel: Ibogaine for Cognitive Enhancement

Tom Feegel: Ibogaine for Cognitive Enhancement

A month ago, I had the privilege of visiting Beond in Cancun, Mexico to experience an ibogaine treatment for cognitive enhancement. Today, I’m joined by Beond CEO Tom Feegel to discuss how this remark...

27 Tammi 20251h 6min

Juan Pablo Capello: A Wakeup Call for Ketamine Telehealth Companies

Juan Pablo Capello: A Wakeup Call for Ketamine Telehealth Companies

Today, I’m joined by Juan Pablo Capello, co-founder and former CEO of New Life Health, a telehealth ketamine therapy service launched in 2021. Juan Pablo has raised concerns about low standards of car...

20 Marras 20241h 4min

Natalie Lyla Ginsberg (MAPS): The FDA, MDMA, and the Future of Psychedelic Therapy

Natalie Lyla Ginsberg (MAPS): The FDA, MDMA, and the Future of Psychedelic Therapy

Today, we’re exploring a critical issue facing the field of psychedelic medicine: the recent FDA rejection of MAPS’ clinical trials to reschedule MDMA for therapeutic use. This setback affects many of...

28 Loka 20241h 3min

Tricia Eastman & Joseph Barsuglia: Ibogaine is Miracle Grow for the Brain

Tricia Eastman & Joseph Barsuglia: Ibogaine is Miracle Grow for the Brain

Today we’re doing something a little different. I’m re-releasing an episode from my personal podcast, Life is a Festival, because it remains one of my favorite interviews ever. This conversation, orig...

18 Loka 20241h 9min

Jennifer Tippett: Understanding Private Practice vs Clinical Trials

Jennifer Tippett: Understanding Private Practice vs Clinical Trials

After the shocking decision of an advisory committee recommendation that the FDA reject MDMA as a treatment for post-traumatic stress disorder, I wanted to speak to someone who understands the differe...

8 Elo 202446min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
tiedenaiset-podcast
vakeva-elama-viisaampi-mieli-vahvempi-keho
meditaatiot-suomeksi
psykopodiaa-podcast
rss-pitaisko-erota
terapiassa
rss-pt-paahtio
rss-uplevel-by-sonja-hannus
voi-hyvin-meditaatiot-2
rss-vapaudu-voimaasi
katilon-kahvitunti
rss-kuumilla-aalloilla
kehorauhaa
rss-seksicast
onnen-kuplia
selviytyjat-tarinoita-elamasta
rss-mighty-finland-podcast
junnut-pelissa
rss-rentoudu-podcast-rentoutumiseen-hanna-viljanmaa